Stock 4554 FUJI PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Fuji Pharma Co., Ltd.

Equities

4554

JP3816200004

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-07-05 am EDT 		5-day change 1st Jan Change
1,507 JPY +2.17% Intraday chart for Fuji Pharma Co., Ltd. +0.74% -13.34%
2023 Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump MT
2023 Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company appears to be poorly valued given its net asset value.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
FUJI PHARMA CO., LTD. Stock Fuji Pharma Co., Ltd.
-13.34% 228M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
C+
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
B+
NOVARTIS AG Stock Novartis AG
+13.83% 220B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
A+
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.57% 159B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4554 Stock
  4. Ratings Fuji Pharma Co., Ltd.